MoonLake Immunotherapeutics
NASDAQ:MLTX
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
38.43
63.86
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
MoonLake Immunotherapeutics
Capital Expenditures
MoonLake Immunotherapeutics
Capital Expenditures Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Capital Expenditures | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
M
|
MoonLake Immunotherapeutics
NASDAQ:MLTX
|
Capital Expenditures
-$284.6k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
ADC Therapeutics SA
NYSE:ADCT
|
Capital Expenditures
-$3.2m
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
N/A
|
|
|
AC Immune SA
NASDAQ:ACIU
|
Capital Expenditures
-CHf652k
|
CAGR 3-Years
38%
|
CAGR 5-Years
16%
|
CAGR 10-Years
N/A
|
|
|
CRISPR Therapeutics AG
NASDAQ:CRSP
|
Capital Expenditures
-$2.4m
|
CAGR 3-Years
69%
|
CAGR 5-Years
18%
|
CAGR 10-Years
N/A
|
|
|
Molecular Partners AG
SIX:MOLN
|
Capital Expenditures
-CHf794k
|
CAGR 3-Years
6%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
N/A
|
|
|
Xlife Sciences AG
SIX:XLS
|
Capital Expenditures
-CHf41.1k
|
CAGR 3-Years
43%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
MoonLake Immunotherapeutics
Glance View
MoonLake Immunotherapeutics is a CH-based company operating in industry. The company is headquartered in Zug, Zug. The company went IPO on 2020-10-20. MoonLake Immunotherapeutics, formerly known as Helix Acquisition Corp, is a Switzerland-based company engaged in the healthcare industry. The Firm is a clinical-stage biopharmaceutical company focused on the development of medicines for immunologic diseases, including inflammatory skin and joint diseases. The firm develops tri-specific nanobody Sonelokimab (SLK) which purpose is to target and penetrate difficult-to-reach inflamed tissues. SLK is a molecule with enhanced enrichment in deep skin & joints and binding of targets. SLK inhibits IL-17A and IL-17F inhibition to treat inflammatory diseases, by independently inhibiting the naturally-occurring IL-17 A/A, A/F and F/F dimers that drive inflammation in patients.
See Also
What is MoonLake Immunotherapeutics's Capital Expenditures?
Capital Expenditures
-284.6k
USD
Based on the financial report for Dec 31, 2023, MoonLake Immunotherapeutics's Capital Expenditures amounts to -284.6k USD.
What is MoonLake Immunotherapeutics's Capital Expenditures growth rate?
Capital Expenditures CAGR 1Y
-1 323%
Over the last year, the Capital Expenditures growth was -1 323%.
You don't have any saved screeners yet
